Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:15pm, Friday, 30'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2022
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
05:20pm, Friday, 30'th Sep 2022 Zacks Investment Research
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
03:03pm, Friday, 30'th Sep 2022
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
12:30pm, Thursday, 29'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has submitted a Bio
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
05:59pm, Wednesday, 28'th Sep 2022 Benzinga
PepGen Inc (NASDAQ: PEPG) reported data from PGN-EDO51's SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities.
SVB notes that PGN-EDO51's safety profile was g
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
12:35pm, Friday, 16'th Sep 2022 Benzinga
Although US stocks closed lower on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stoc
Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
11:00am, Wednesday, 14'th Sep 2022 GlobeNewswire Inc.
With current cash and projected revenue, offering is expected to fund operations to profitability With current cash and projected revenue, offering is expected to fund operations to profitability
Sarepta prices almost $1 billion convertible bond offering
07:10am, Wednesday, 14'th Sep 2022
Sarepta Therapeutics Inc. SRPT, -9.77% said Wednesday it has priced $980 million of convertible senior unsecured notes that mature in September of 2027. The company will reduce the potential dilution
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
08:41pm, Monday, 12'th Sep 2022 GlobeNewswire Inc.
– With current cash and projected revenue, offering is expected to fund operations to profitability
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
03:20pm, Monday, 12'th Sep 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
12:47pm, Monday, 12'th Sep 2022
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
Arm Vs. Qualcomm In A Huge Lawsuit With Little Coverage, I Explain
07:15am, Monday, 12'th Sep 2022 Seeking Alpha
I had no idea that ARM was suing Qualcomm over IP infringement. See why if QCOM is successful in the laptop CPU market, it could easily add $100B in market cap.
Analyst Ratings for Sarepta Therapeutics
07:27pm, Thursday, 08'th Sep 2022 Benzinga
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
5
0
0
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
05:31pm, Thursday, 08'th Sep 2022 Benzinga
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
The analyst notes concerns regarding the Phase 3 EMBARK study, with a modest probabili
Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA
02:08pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.
